Possis Medical gets $17 million financing:
This article was originally published in Clinica
Executive Summary
Possis Medical has secured a financing commitment for up to $17 million from a group of institutional investors. The Minneapolis-based company will use the proceeds for research and development into applications for its AngioJet Rheolytic Thrombectomy system - which is sold in the US for the treatment of dialysis access graft thrombosis - as well as expanding its sales and marketing operations. The company says the AngioJet system can be used to quickly remove blood clots from vessels. It has been designed to treat a range of conditions, including heart attacks, stroke, dialysis access failure, pulmonary embolism and deep vein thrombosis.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.